stockportfolio.pro
ACADIA Pharmaceuticals Inc. (ACAD)
Healthcare · Biotechnology · NasdaqGS
ACADIA Pharmaceuticals Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.33M | $124.90M | $223.81M | $339.08M | $441.75M | $484.14M | $517.24M | $726.44M | $957.80M | $1.07B |
| Gross profit | $14.25M | $115.82M | $211.43M | $327.73M | $431.54M | $473.30M | $507.07M | $684.80M | $875.96M | $982.51M |
| Net income | $-271.39M | $-289.40M | $-245.19M | $-235.26M | $-281.58M | $-167.87M | $-215.97M | $-61.29M | $226.45M | $391.00M |
| Net margin | -1565.9% | -231.7% | -109.6% | -69.4% | -63.7% | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% |
Source: ACADIA Pharmaceuticals Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of ACADIA Pharmaceuticals Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ACAD in your portfolio →
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc. — frequently asked questions
What is ACADIA Pharmaceuticals Inc.'s revenue?
ACADIA Pharmaceuticals Inc. (ACAD) reported revenue of $1.07B for fiscal year 2025, up 11.9% from the prior year, according to its SEC filings.
Is ACADIA Pharmaceuticals Inc. profitable?
Yes. ACAD earned net income of $391.00M in fiscal 2025, a net margin of 36.5%.
What is ACAD's P/E ratio?
ACADIA Pharmaceuticals Inc. trades at a price-to-earnings ratio of about 9.7 based on the latest data in our nightly-refreshed cache.
How fast is ACADIA Pharmaceuticals Inc. growing?
ACAD's revenue grew at roughly 19.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from ACADIA Pharmaceuticals Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.